: 2017.10.19 목 08:14
메디컬 미디어 협의회
IPF World Week 2017: Boehringer Ingelheim helps healthcare professionals to ‘listen for the sounds of IPF’
IPF is a progressive and debilitating disease which causes continual and ir...
Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV
Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) ...
AstraZeneca Presents Tagrisso(osimertinib) Data in Patients with EGFR T790M-Mutation Positive Lung Cancer and Central Nervous System Metastases
AstraZeneca today reported further evidence that Tagrisso (osimertinib), the potential new standard of care for adult pa...
ATS 2017 Spiriva Respimat improves breathing for people with asthma regardless of BMI or allergic status
Boehringer Ingelheim today announced new analyses that provide further evidence that adding tiotropium Respimat® (Sp...
Takeda Reports FY2016 Full Year Results and Issues FY2017 Guidance
Takeda Pharmaceutical Company Limited (TOKYO:4502):Delivered substantial profit growth versus prior year· Underlying Rev...
US FDA Expands Approval of Tiotropium Respimat for Maintenance Treatment of Asthma in Children
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved tiotropium Respimat® (mar...
Takeda Recognized as One of the Global 100 Most Sustainable Corporations for Second Consecutive Year
Takeda Pharmaceutical Company Limited [TOKYO:4502], (“Takeda”) is proud to be named by Corporate Knights to the 2017 Glo...
Boehringer Ingelheim HCP Survey: Nearly 20% of newly diagnosed lung cancer patients tested for EGFR mutations at risk of missing out on personalised treatments for their disease
Results from a new international survey of physicians revealed more patients with advanced non-small cell lung cancer (N...
Takeda and Zydus Cadila partner to address the global threat of Chikungunya
Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) and Zydus Cadila today announced a partnership to tackle c...
Boehringer Ingelheim launches RE-VECTO global program to capture data on Praxbind usage in clinical practice
Boehringer Ingelheim launches RE-VECTO global program to capture data on Praxbind® usage in clinical practice Praxbind® ...
Takeda Receives Marketing Authorization in Canada for NINLARO in Relapsed·Refractory Multiple Myeloma
Takeda Pharmaceutical Company Limited (TSE:4502) today announced Takeda Canada has received approval from Health Canada ...
Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma
Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin...
Boehringer Ingelheim and University of Dundee collaborate to develop new class of medicines
INGELHEIM, GERMANY & DUNDEE, SCOTLAND--(Business Wire/Korea Newswire) July 15, 2016 -- Scotland--(BUSINESS WIRE)-- Boehr...
ASTRAZENECA’S COMBINATION OF DURVALUMAB WITH TREMELIMUMAB SHOWS CLINICAL ACTIVITY IN NON-SMALL CELL LUNG CANCER IRRESPECTIVE OF PD-L1 STATUS
LONDON--AstraZeneca and MedImmune, its global biologics research and development arm, today announced publication in The...
Takeda and enGene Establish Strategic Alliance to Develop Novel Therapeutics for Gastrointestinal Diseases
Takeda Pharmaceutical Company Ltd. (TOKYO:4502) (http://goo.gl/eX9kbP) and enGene, Inc. today announced a strategic alli...
Boehringer Ingelheim Invests in Europe: Pharma Company Expands Biopharmaceutical Production at Vienna Site
Boehringer Ingelheim will make a significant investment in biopharmaceutical production at its Vienna (Austria) site. Th...
Merck and Pfizer Initiate Two Phase III Studies of Investigational Immunotherapy Avelumab in Advanced Gastric and Gastro-esophageal Junction Cancers
Merck and Pfizer today announced the initiation of two Phase III studies of avelumab*, an investigational, fully human a...
Takeda Presents Data from Phase 3 TOURMALINE-MM1 Study for NINLARO, First and Only Once-Weekly Oral Proteasome Inhibitor Recently Approved for Multiple Myeloma
Takeda Pharmaceutical Company Limited (TSE:4502, http://goo.gl/eX9kbP) today announced results from the TOURMALINE-MM1 t...
Merck and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy Avelumab in Merkel Cell Carcinoma
Merck and Pfizer today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for ...
Jardiance demonstrated cardiovascular risk reduction in people with type 2 diabetes at high risk for CV events
Boehringer Ingelheim and Eli Lilly and Company today announced positive top-line results from EMPA-REG OUTCOME®. This is...
명칭 : (주)메디컬헤럴드
정기간행물 등록번호 : 서울 아 00603
등록일 : 2008년 6월 23일
제호 : 메디컬헤럴드(The Medical Herald)
발행·편집인 : 우정헌
주소: (우 06178) 서울특별시 강남구 테헤란로 84길 14 지어로빌딩 10층
발행일 : 2008년 4월 1일
전화 : 02-555-7482
팩스 : 02-565-0938
청소년보호책임자 : 우정헌
(우)05836 서울 송파구 법원로 9길 26 1017호 메디컬 미디어 협의회(에이치비지니스파크, 문정동)
2017 메디컬헤럴드. All rights reserved.
Back to Top